Brief: Neurobo Pharmaceuticals Completes Last Patient Last Visit In Its Phase 2A Clinical Trial Evaluating Da-1241 For The Treatment Of Mash
04/11/2024 14:17
Nov 4 (Reuters) - Neurobo Pharmaceuticals Inc NRBO.O :
* NEUROBO PHARMACEUTICALS COMPLETES LAST PATIENT LAST VISIT
IN ITS
PHASE 2A CLINICAL TRIAL EVALUATING DA-1241 FOR THE TREATMENT OF
MASH
* NEUROBO PHARMACEUTICALS INC - TOPLINE DATA READOUT
EXPECTED IN
DECEMBER 2024
Source text: ID:nPn58XKJXa
Further company coverage: NRBO.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on MetaVia
See all newsMetaVia Inc reports results for the quarter ended June 30 - Earnings Summary
MetaVia Q2 net loss widens on higher R&D spending
MetaVia Inc expected to post a loss of 82 cents a share - Earnings Preview
Brief: Biostem Technologies Announces Appointment Of Three New Members To Its Board Of Directors
MetaVia Q1 net loss widens slightly as expenses rise